<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-94310" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Salmeterol</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Adams</surname>
            <given-names>Bryan S.</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nguyen</surname>
            <given-names>Hoang</given-names>
          </name>
          <aff>NOVA Southeastern University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bryan Adams declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hoang Nguyen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>23</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-94310.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Salmeterol is a medication used in the management and treatment of asthma and COPD. It is in the beta-2 adrenergic agonist class medications. This activity reviews the indications, mechanism of action, and contraindications for salmeterol as a valuable agent in treating asthma and COPD. This activity will highlight the mechanism of action, adverse event profile, and dosing pertinent for members of the interprofessional team in the treatment of patients with asthma and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of salmeterol.</p></list-item><list-item><p>Describe the potential adverse effects associated with salmeterol.</p></list-item><list-item><p>Review the appropriate administration for salmeterol.</p></list-item><list-item><p>Summarize some interprofessional team strategies for improving care coordination and communication to advance proper asthma treatment and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=94310&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=94310">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-94310.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Salmeterol is a highly selective, long-acting beta-2 adrenergic agonist indicated in the treatment of asthma, maintenance of airflow obstruction in chronic obstructive pulmonary disease (COPD), and prevention of exercise-induced bronchospasm (EIB).<xref ref-type="bibr" rid="article-94310.r1">[1]</xref><xref ref-type="bibr" rid="article-94310.r2">[2]</xref><xref ref-type="bibr" rid="article-94310.r3">[3]</xref><xref ref-type="bibr" rid="article-94310.r4">[4]</xref>&#x000a0;Salmeterol is used in combination with inhaled corticosteroids in the treatment of asthma.<xref ref-type="bibr" rid="article-94310.r5">[5]</xref>&#x000a0;It can be useful in both the maintenance of asthma and the prevention of asthma attacks. It is usually prescribed for severe persistent asthma not properly controlled using a short-acting beta-adrenergic agonist and a corticosteroid. Salmeterol is not indicated in patients with mild asthma who are well-maintained on short-acting beta-agonists. Salmeterol monotherapy is&#x000a0;a contraindication for treating asthma patients due to the increased risk of mortality. Salmeterol administration with concomitant inhaled corticosteroid (ICS) has significantly reduced asthma mortality.<xref ref-type="bibr" rid="article-94310.r6">[6]</xref>&#x000a0;Salmeterol can, however, be used as a monotherapy in the treatment of COPD, particularly as a maintenance treatment.<xref ref-type="bibr" rid="article-94310.r7">[7]</xref>&#x000a0;Salmeterol has been shown to increase FEV1 and the FEV1/FVC ratio in both asthma and COPD patients.<xref ref-type="bibr" rid="article-94310.r8">[8]</xref></p>
        <p>Following the approval in 1994 of salmeterol xinafoate, the FDA approved fluticasone propionate/salmeterol (FP/SAL) as a fixed-dose combination therapy for the treatment of asthma and COPD. The fluticasone/salmeterol combination provides sustained bronchodilation, prevention of exacerbation, improved lung function, and reduced rescue medicine use.<xref ref-type="bibr" rid="article-94310.r9">[9]</xref></p>
        <p>Salmeterol is ten times more potent than its chemical analog, albuterol. Additionally, it has a much higher beta-2/beta-1 selectivity ratio than albuterol, with a ratio of 50,000&#x000a0;to 1 vs. 650&#x000a0;to 1.<xref ref-type="bibr" rid="article-94310.r10">[10]</xref></p>
        <p>A head-to-head study comparing the use of salmeterol and salbutamol (albuterol) revealed clinically superior results of inhaled salmeterol, providing sustained bronchodilatation and better prevention of the symptoms of asthma than salbutamol. These results measured pulmonary function, peak expiratory flow, the need for a supplemental bronchodilator, frequency of nocturnal awakening, and the occurrence and severity of daily symptoms of asthma.<xref ref-type="bibr" rid="article-94310.r10">[10]</xref>&#x000a0;</p>
        <p>Salmeterol is used for prophylaxis of mild to moderate asthma and COPD and should never be used to treat acute bronchospasm.</p>
      </sec>
      <sec id="article-94310.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Salmeterol belongs to the group of drugs called beta-2 agonists. Beta-2 agonists are G protein-linked second messengers. The Gs protein stimulates adenylyl cyclase, which converts ATP to cAMP. Subsequently, cAMP activates protein kinase A, inhibiting myosin light chain kinase (present in smooth muscle). This cascade results in the relaxation of bronchiolar smooth muscle, bronchodilation, and increased bronchiole airflow.<xref ref-type="bibr" rid="article-94310.r11">[11]</xref><xref ref-type="bibr" rid="article-94310.r12">[12]</xref><xref ref-type="bibr" rid="article-94310.r13">[13]</xref></p>
        <p>In human lungs, salmeterol&#x000a0;also inhibits mast cell mediators, including histamine, leukotrienes, and prostaglandins; this suppression leads to&#x000a0;decreased inflammation. Bronchodilation remains the primary function of salmeterol; its anti-inflammatory properties are present to a much lesser degree.&#x000a0;</p>
        <p>Salmeterol&#x02019;s molecular structure confers its characteristic, extended duration of action. Its elongated lipophilic side chain facilitates repeated activation of the beta-2 receptor. The side chain binds to the so-called &#x0201c;exosite&#x0201d; adjacent to beta-2 adrenergic receptors. The active portion of the molecule is allowed to remain at the receptor site and continuously engage and disengage with the receptor.<xref ref-type="bibr" rid="article-94310.r14">[14]</xref>&#x000a0;Due to this unique molecular structure, a single inhaled dose of salmeterol lasts approximately 12 hours compared to salbutamol, which lasts 4 to 6 hours. Salmeterol given twice daily in the management of mild-to-moderate asthma has proven clinically superior to albuterol given either regularly or intermittently as needed.<xref ref-type="bibr" rid="article-94310.r10">[10]</xref></p>
        <p>
<bold>Metabolism</bold>
</p>
        <p>Salmeterol is metabolized predominantly through CYP3A4, an isoform of cytochrome P450. CYP3A4 is responsible for the aliphatic oxidation of the salmeterol base. Salmeterol is extensively metabolized by hydroxylation into alpha-hydroxy-salmeterol and subsequently eliminated through feces and urine. Salmeterol is 57.4% eliminated in the feces and 23% in the urine.<xref ref-type="bibr" rid="article-94310.r15">[15]</xref><xref ref-type="bibr" rid="article-94310.r16">[16]</xref></p>
        <p>At recommended doses, systemic concentrations of salmeterol are low or undetectable. Only at very high doses are blood concentrations increased.&#x000a0;</p>
        <p>At a very low therapeutic dose, it is unlikely to observe any clinically relevant interactions as a consequence of co-administration of other medications metabolized through CYP3A4.<xref ref-type="bibr" rid="article-94310.r16">[16]</xref> Specific guidelines for dosage adjustment in renal or hepatic impairment are not currently available. However, caution is necessary for patients with severe liver dysfunction and subsequent clearance decrease. Additionally, the use of potent CYP34A inhibitors is not recommended because increased cardiovascular and systemic corticosteroid adverse effects may occur. These inhibitors include but are not limited to ritonavir, atazanavir, indinavir, nelfinavir, saquinavir, itraconazole, ketoconazole, nefazodone, clarithromycin, and telithromycin.<xref ref-type="bibr" rid="article-94310.r17">[17]</xref></p>
      </sec>
      <sec id="article-94310.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Salmeterol comes in a variety of dosing forms and strengths. The most common form is a fixed-dose combination containing both fluticasone propionate and salmeterol. As salmeterol monotherapy is contraindicated in the treatment of asthma, clinicians often use fixed-dose combinations to ensure adherence to both drugs.<xref ref-type="bibr" rid="article-94310.r6">[6]</xref><xref ref-type="bibr" rid="article-94310.r9">[9]</xref></p>
        <p>Salmeterol is currently available as an oral inhalation powder and an oral inhalation aerosol. Inhalation powder is available in 3 doses of fluticasone (100 mcg, 250 mcg, 500 mcg) and a fixed dose (50 mcg) of salmeterol. An aerosol metered-dose inhaler (MDI) is also available in 3 doses of fluticasone (45 mcg, 115 mcg, 230 mcg) and a fixed dose (21 mcg) of salmeterol. A hydrofluoralkane propellant delivers the metered-dose inhaler. In an active-controlled, 12-week trial, improvements in morning peak expiratory flow (PEF) observed with the 500/50 mcg formulation were similar to improvements seen with the 230/21 formulation. Though the mechanism of delivery and dose vary, research showed efficacy to be similar across treatments.<xref ref-type="bibr" rid="article-94310.r18">[18]</xref>&#x000a0;Paradoxical bronchospasm has been reported in patients using metered-dose inhalers but not dry powder inhalers.<xref ref-type="bibr" rid="article-94310.r19">[19]</xref></p>
        <p>For the treatment of asthma in patients aged 12 years and older, one inhalation of fluticasone/salmeterol 100/50, 250/50, 500/50 mcg inhalation powder is taken twice daily.<xref ref-type="bibr" rid="article-94310.r1">[1]</xref>&#x000a0;The starting dosage is determined based on asthma severity. Conversely, two inhalations of fluticasone/salmeterol 45/21, 115/21, 230/21 mcg inhalation aerosol are dosed twice daily. After inhalation, patients should understand the need to rinse their mouths with water and, without swallowing, spit out the contents to avoid oral candidiasis.<xref ref-type="bibr" rid="article-94310.r20">[20]</xref></p>
        <p>For the treatment of asthma in children between the ages of 4 and 11, the standard recommendation is one inhalation of fluticasone/ salmeterol 100/50 mcg twice daily.<xref ref-type="bibr" rid="article-94310.r1">[1]</xref> Safety and efficacy have not been established in children less than four years old</p>
        <p>For maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, the recommendation is one inhalation of 250/50 mcg twice daily, approximately 12 hours apart.<xref ref-type="bibr" rid="article-94310.r2">[2]</xref></p>
        <p>For the prevention of exercise-induced bronchospasm (EIB), single-agent administration of salmeterol inhalation powder may be clinically indicated in patients without persistent asthma. In these cases, one inhalation of 50 mcg, taken 20&#x000a0;to 30 minutes before exercise, has been shown to protect against EIB. Generally, the desired bronchodilation effects last 9 hours in adults and 12 hours in patients 4 to 11 years old. In patients with persistent asthma, monotherapy is contraindicated.<xref ref-type="bibr" rid="article-94310.r3">[3]</xref></p>
      </sec>
      <sec id="article-94310.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most common adverse reactions of salmeterol (incidence &#x02265;3%) in asthmatics include upper respiratory infection or inflammation, oral candidiasis, pharyngitis, bronchitis, dysphonia, headaches, cough, nausea, and vomiting. In patients with chronic obstructive pulmonary disease, the most common adverse effects include pneumonia, throat irritation, viral respiratory infections, oral candidiasis, dysphonia, headaches, and musculoskeletal pains.<xref ref-type="bibr" rid="article-94310.r21">[21]</xref></p>
        <p>Immediate hypersensitivity reactions may occur. Patients may present with urticaria, rash, angioedema, bronchospasm, headache, tremor, or anaphylaxis.&#x000a0;</p>
        <p>More severe adverse effects associated with salmeterol overdose are characterized by excessive beta-adrenergic stimulation to the heart. Although salmeterol is a highly selective beta-2 agonist, it still exhibits some beta-1 effects and can cause cardiac effects.</p>
        <p>These symptoms include angina, tachycardia, hypertension, hypotension, arrhythmia, palpitation, and fatigue. These undesirable pharmacologic effects are predominantly a result of reflex activation in response to peripheral vasodilation, hypoxemia, hypokalemia, and direct stimulation of cardiac beta-adrenoceptors.<xref ref-type="bibr" rid="article-94310.r22">[22]</xref></p>
        <p>Paradoxical bronchospasm, laryngeal spasm, and throat swelling can occur. In COPD patients, long-acting beta-agonists (LABA) have been shown to increase the risk of cardiac failure.<xref ref-type="bibr" rid="article-94310.r23">[23]</xref></p>
      </sec>
      <sec id="article-94310.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Hypersensitivity is a contraindication for salmeterol.&#x000a0;It&#x000a0;is contraindicated in patients with a known hypersensitivity to any ingredient in the preparation, including lactose and milk protein.<xref ref-type="bibr" rid="article-94310.r24">[24]</xref></p>
        <p>Salmeterol is contraindicated in patients who have had adverse reactions to salmeterol in the past. It should not be used for status asthmaticus or other acute asthma episodes. Salmeterol should not be used in combination with other long-acting beta-agonists.&#x000a0;Studies have shown an increased risk for death in asthma patients taking salmeterol vs. placebo; this risk was highest for African-American patients.<xref ref-type="bibr" rid="article-94310.r25">[25]</xref></p>
        <p>There is an FDA black box warning for asthma patients due to the increased incidence of asthma-related deaths with this medication.&#x000a0;Salmeterol should not be used as a monotherapy&#x000a0;in asthma patients. Clinicians should only use it as an adjunct medication in patients who have failed other asthma therapies, such as low to medium-dose inhaled steroids or those with severe asthma necessitating two maintenance therapies.</p>
        <p>While not strictly contraindications, salmeterol use requires caution in patients with an existing cardiovascular disorder, convulsive disorder, hepatic impairment, diabetes mellitus, hyperthyroidism/thyrotoxicosis, or&#x000a0;who use CYP3A inhibitors, as this may increase toxicity and prolong the patient&#x02019;s QT interval. There is a (usually transient) risk of hypokalemia; therefore, salmeterol use merits caution in patients with hypokalemia.</p>
      </sec>
      <sec id="article-94310.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Monitoring parameters for salmeterol include heart rate, blood pressure, pulmonary function, forced expiratory volume, peak expiratory flow, frequency of nocturnal awakenings, central nervous system stimulation, and occurrence and severity of asthma symptoms.<xref ref-type="bibr" rid="article-94310.r26">[26]</xref></p>
        <p>If there is a concern for any of the conditions noted above in the contraindication section, it may be helpful to periodically monitor blood glucose, potassium, thyroid function, hepatic function, and/or the QT interval if the patient is concomitantly taking CYP3A4 inhibitors.</p>
        <p>Patients with hepatic impairment require close monitoring as decreased liver function may lead to salmeterol accumulation in the plasma.<xref ref-type="bibr" rid="article-94310.r17">[17]</xref></p>
      </sec>
      <sec id="article-94310.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>There are reports of sympathomimetic syndrome with hyperlactatemia and metabolic acidosis after the intentional inhalation of salmeterol in a suicide attempt. Patients who overdose commonly present with heart palpitation, chest pain, hypophosphatemia, hypokalemia, lactic acidosis, ST-segment depression, and sinus tachycardia. Patients may also present with angina, hypotension, hypertension, dizziness, nausea, fatigue, malaise, insomnia, and muscle cramps. Overdose with salmeterol can lead to prolongation of the QT interval resulting in ventricular arrhythmias.<xref ref-type="bibr" rid="article-94310.r22">[22]</xref></p>
        <p>The standard treatment for symptomatic salmeterol overdose is supportive and should include intravenous fluids, careful potassium supplementation, a cardioselective beta-blocker, and cardiac monitoring.</p>
      </sec>
      <sec id="article-94310.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>As most patients with COPD and severe asthma will require lifetime treatment with long-acting beta-2 agonists, a patient-centered approach involving multi-disciplinary coordination is requisite. At the level of primary care, the employment of respiratory therapists has shown improvement in the quality of asthma care. Patient outcomes have improved with more specialized care, decreasing&#x000a0;the necessity for rescue inhaler&#x000a0;use and overall symptom reduction. Additionally, proper inhaler device technique and spirometry for diagnosis increased in facilities with a designated respiratory care specialist (RCS). Pharmacists assist in verifying medication dosing and reinforcing proper inhalation technique. Nurses can educate, monitor care, and assess therapeutic effectiveness. In geriatric populations, long-term care facilities ensure medication compliance and appropriate outpatient care. <xref ref-type="bibr" rid="article-94310.r27">[27]</xref>&#x000a0;An interprofessional team-based approach involving physicians, respiratory therapists, respiratory care specialists, specialty-trained nurses, pharmacists, and patients leads to improved symptom control, decreased acute exacerbations, and improved quality of life. [Level 5]&#x000a0;</p>
      </sec>
      <sec id="article-94310.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=94310&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=94310">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/94310/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=94310">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-94310.s11">
        <title>References</title>
        <ref id="article-94310.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D'Alonzo</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Tolep</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Salmeterol in the treatment of chronic asthma.</article-title>
            <source>Am Fam Physician</source>
            <year>1997</year>
            <month>Aug</month>
            <volume>56</volume>
            <issue>2</issue>
            <fpage>558</fpage>
            <page-range>558-62</page-range>
            <pub-id pub-id-type="pmid">9262535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-94310.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yawn</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Raphiou</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hurley</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Dalal</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD.</article-title>
            <source>Int J Chron Obstruct Pulmon Dis</source>
            <year>2010</year>
            <month>Jun</month>
            <day>03</day>
            <volume>5</volume>
            <fpage>165</fpage>
            <page-range>165-78</page-range>
            <pub-id pub-id-type="pmid">20631816</pub-id>
          </element-citation>
        </ref>
        <ref id="article-94310.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bronsky</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Pearlman</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Pobiner</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Stahl</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Prevention of exercise-induced bronchospasm in pediatric asthma patients: A comparison of two salmeterol powder delivery devices.</article-title>
            <source>Pediatrics</source>
            <year>1999</year>
            <month>Sep</month>
            <volume>104</volume>
            <issue>3 Pt 1</issue>
            <fpage>501</fpage>
            <page-range>501-6</page-range>
            <pub-id pub-id-type="pmid">10469776</pub-id>
          </element-citation>
        </ref>
        <ref id="article-94310.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Green</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Prevention of exercise induced asthma by inhaled salmeterol xinafoate.</article-title>
            <source>Arch Dis Child</source>
            <year>1992</year>
            <month>Aug</month>
            <volume>67</volume>
            <issue>8</issue>
            <fpage>1014</fpage>
            <page-range>1014-7</page-range>
            <pub-id pub-id-type="pmid">1355645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-94310.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Popov</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>De Niet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vanderbist</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Budesonide/salmeterol in fixed-dose combination for the treatment of asthma.</article-title>
            <source>Expert Rev Respir Med</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>113</fpage>
            <page-range>113-25</page-range>
            <pub-id pub-id-type="pmid">26677916</pub-id>
          </element-citation>
        </ref>
        <ref id="article-94310.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lommatzsch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lindner</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Edner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bratke</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kuepper</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Virchow</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Adverse effects of salmeterol in asthma: a neuronal perspective.</article-title>
            <source>Thorax</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>64</volume>
            <issue>9</issue>
            <fpage>763</fpage>
            <page-range>763-9</page-range>
            <pub-id pub-id-type="pmid">19237390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-94310.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santus</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Radovanovic</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Paggiaro</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Papi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sanduzzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scichilone</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Braido</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol.</article-title>
            <source>Eur J Intern Med</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>379</fpage>
            <page-range>379-84</page-range>
            <pub-id pub-id-type="pmid">26049917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-94310.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grove</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lipworth</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Ramage</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ingram</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Winter</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Dhillon</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease.</article-title>
            <source>Thorax</source>
            <year>1996</year>
            <month>Jul</month>
            <volume>51</volume>
            <issue>7</issue>
            <fpage>689</fpage>
            <page-range>689-93</page-range>
            <pub-id pub-id-type="pmid">8882074</pub-id>
          </element-citation>
        </ref>
        <ref id="article-94310.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calzetta</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ritondo</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Matera</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Cazzola</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rogliani</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of fluticasone propionate/salmeterol for the treatment of COPD: a systematic review.</article-title>
            <source>Expert Rev Respir Med</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>14</volume>
            <issue>6</issue>
            <fpage>621</fpage>
            <page-range>621-635</page-range>
            <pub-id pub-id-type="pmid">32168461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-94310.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pearlman</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Chervinsky</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>LaForce</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Seltzer</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Southern</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Kemp</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Dockhorn</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liddle</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Yancey</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <article-title>A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma.</article-title>
            <source>N Engl J Med</source>
            <year>1992</year>
            <month>Nov</month>
            <day>12</day>
            <volume>327</volume>
            <issue>20</issue>
            <fpage>1420</fpage>
            <page-range>1420-5</page-range>
            <pub-id pub-id-type="pmid">1357554</pub-id>
          </element-citation>
        </ref>
        <ref id="article-94310.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Billington</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Penn</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>IP</given-names>
              </name>
            </person-group>
            <article-title>&#x003b2;<sub>2</sub> Agonists.</article-title>
            <source>Handb Exp Pharmacol</source>
            <year>2017</year>
            <volume>237</volume>
            <fpage>23</fpage>
            <page-range>23-40</page-range>
            <pub-id pub-id-type="pmid">27878470</pub-id>
          </element-citation>
        </ref>
        <ref id="article-94310.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barisione</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Baroffio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Crimi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Brusasco</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Beta-Adrenergic Agonists.</article-title>
            <source>Pharmaceuticals (Basel)</source>
            <year>2010</year>
            <month>Mar</month>
            <day>30</day>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>1016</fpage>
            <page-range>1016-1044</page-range>
            <pub-id pub-id-type="pmid">27713285</pub-id>
          </element-citation>
        </ref>
        <ref id="article-94310.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Song</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Salmeterol, agonist of &#x003b2;2-aderenergic receptor, prevents systemic inflammation via inhibiting NLRP3 inflammasome.</article-title>
            <source>Biochem Pharmacol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>150</volume>
            <fpage>245</fpage>
            <page-range>245-255</page-range>
            <pub-id pub-id-type="pmid">29447945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-94310.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Butchers</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Coleman</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Nials</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Strong</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sumner</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Vardey</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Whelan</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>The pharmacology of salmeterol.</article-title>
            <source>Life Sci</source>
            <year>1993</year>
            <volume>52</volume>
            <issue>26</issue>
            <fpage>2131</fpage>
            <page-range>2131-43</page-range>
            <pub-id pub-id-type="pmid">8099695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-94310.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manchee</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Eddershaw</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Ranshaw</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Herriott</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Bayliss</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Tarbit</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>The aliphatic oxidation of salmeterol to alpha-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A.</article-title>
            <source>Drug Metab Dispos</source>
            <year>1996</year>
            <month>May</month>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>555</fpage>
            <page-range>555-9</page-range>
            <pub-id pub-id-type="pmid">8723736</pub-id>
          </element-citation>
        </ref>
        <ref id="article-94310.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cazzola</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Testi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Matera</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics of salmeterol.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2002</year>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <page-range>19-30</page-range>
            <pub-id pub-id-type="pmid">11825095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-94310.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teply</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hilleman</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Current trends in the treatment of asthma: focus on the simultaneous administration of salmeterol/fluticasone.</article-title>
            <source>J Asthma Allergy</source>
            <year>2010</year>
            <month>Mar</month>
            <day>11</day>
            <volume>3</volume>
            <fpage>1</fpage>
            <page-range>1-8</page-range>
            <pub-id pub-id-type="pmid">21437034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-94310.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bronsky</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bucholtz</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Busse</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Chervinsky</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Condemi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ghafouri</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Hudson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lakshminarayan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lockey</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Reese</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Comparison of inhaled albuterol powder and aerosol in asthma.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>1987</year>
            <month>May</month>
            <volume>79</volume>
            <issue>5</issue>
            <fpage>741</fpage>
            <page-range>741-7</page-range>
            <pub-id pub-id-type="pmid">3553277</pub-id>
          </element-citation>
        </ref>
        <ref id="article-94310.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilkinson</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Bradding</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Holgate</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Howarth</surname>
                <given-names>PH</given-names>
              </name>
            </person-group>
            <article-title>Paradoxical bronchoconstriction in asthmatic patients after salmeterol by metered dose inhaler.</article-title>
            <source>BMJ</source>
            <year>1992</year>
            <month>Oct</month>
            <day>17</day>
            <volume>305</volume>
            <issue>6859</issue>
            <fpage>931</fpage>
            <page-range>931-2</page-range>
            <pub-id pub-id-type="pmid">1360855</pub-id>
          </element-citation>
        </ref>
        <ref id="article-94310.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Godara</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Godara</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Khullar</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Impact of inhalation therapy on oral health.</article-title>
            <source>Lung India</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>272</fpage>
            <page-range>272-5</page-range>
            <pub-id pub-id-type="pmid">22084541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-94310.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spencer</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Jarvis</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Salmeterol/fluticasone propionate combination.</article-title>
            <source>Drugs</source>
            <year>1999</year>
            <month>Jun</month>
            <volume>57</volume>
            <issue>6</issue>
            <fpage>933</fpage>
            <page-range>933-40; discussion 941-3</page-range>
            <pub-id pub-id-type="pmid">10400406</pub-id>
          </element-citation>
        </ref>
        <ref id="article-94310.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manara</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hantson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vanpee</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Thys</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Lactic acidosis following intentional overdose by inhalation of salmeterol and fluticasone.</article-title>
            <source>CJEM</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>14</volume>
            <issue>6</issue>
            <fpage>378</fpage>
            <page-range>378-81</page-range>
            <pub-id pub-id-type="pmid">23131487</pub-id>
          </element-citation>
        </ref>
        <ref id="article-94310.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Correlation of Inhaled Long-Acting Bronchodilators With Adverse Cardiovascular Outcomes in Patients With Stable COPD: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.</article-title>
            <source>J Cardiovasc Pharmacol</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>74</volume>
            <issue>3</issue>
            <fpage>255</fpage>
            <page-range>255-265</page-range>
            <pub-id pub-id-type="pmid">31306366</pub-id>
          </element-citation>
        </ref>
        <ref id="article-94310.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robles</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Motheral</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Hypersensitivity reaction after inhalation of a lactose-containing dry powder inhaler.</article-title>
            <source>J Pediatr Pharmacol Ther</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>206</fpage>
            <page-range>206-11</page-range>
            <pub-id pub-id-type="pmid">25309152</pub-id>
          </element-citation>
        </ref>
        <ref id="article-94310.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rider</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>A safety review of long-acting beta2-agonists in patients with asthma.</article-title>
            <source>J Am Osteopath Assoc</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>106</volume>
            <issue>9</issue>
            <fpage>562</fpage>
            <page-range>562-7</page-range>
            <pub-id pub-id-type="pmid">17079526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-94310.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cazzola</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Imperatore</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Salzillo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Di Perna</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Calderaro</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Imperatore</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Matera</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia.</article-title>
            <source>Chest</source>
            <year>1998</year>
            <month>Aug</month>
            <volume>114</volume>
            <issue>2</issue>
            <fpage>411</fpage>
            <page-range>411-5</page-range>
            <pub-id pub-id-type="pmid">9726723</pub-id>
          </element-citation>
        </ref>
        <ref id="article-94310.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hart</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Millard</surname>
                <given-names>MW</given-names>
              </name>
            </person-group>
            <article-title>Approaches to chronic disease management for asthma and chronic obstructive pulmonary disease: strategies through the continuum of care.</article-title>
            <source>Proc (Bayl Univ Med Cent)</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>223</fpage>
            <page-range>223-9</page-range>
            <pub-id pub-id-type="pmid">20671816</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
